The distribution and expression profiles of human aspartyl/asparaginyl beta-hydroxylase in tumor cell lines and human tissues

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1257-1264

  Yang, Hui ^a   Song, Kai ^a   Xue, Tian ^b   Xue, Xiao Ping ^a   Huyan, Ting ^a   Wang, Wei ^a   Wang, Hua ^a  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

Author keywords

Aspartyl beta hydroxylase; Carcinomas; Tumor marker

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; HUMAN ASPARTYLASPARAGINYL BETA HYDROXYLASE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HAAH; OXYGENASE; PLASMID DNA; RECOMBINANT ENZYME; RECOMBINANT HUMAN ASPARTYLASPARAGINYL BETA HYDROXYLASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLADDER CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOMA; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNIZATION; IMMUNOFLUORESCENCE CELL STAINING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LARYNX CANCER; LIVER CARCINOMA; MOUSE; NONHUMAN; OSTEOBLAST; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE; TUMOR; TUMOR CELL; TUMOR CELL LINE; UNIVERSITY HOSPITAL; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHINA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIXED FUNCTION OXYGENASES; NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78149353327     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000980     Document Type: Article

References (27)

1. Taouli B, Losada M, Holland A and Krinsky G: Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 127: 144-152, 2004.
2. Baron RL and Brancatelli G: Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127: 133-143, 2004.
3. Suriawinata A and Xu R: An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 24: 77-88, 2004.
4. Feitelson MA, Pan J and Lian Z: Early molecular and genetic determinants of primary liver malignancy. Surg Clin North Am 84: 339-354, 2004.
5. Dinchuk JE, Focht RJ, Kelley JA, Henderson NL, Zolotarjova NI, Wynn R, Neff NT Link J, Huber RM, Burn TC, Rupar MJ, Cunningham MR, Selling BH, Ma J, Stern AA, Hollis GF, Stein RB and Friedman PA: Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem 277: 12970-12977, 2002.
6. Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J, O'Neil KT, Focht RJ, Scully MS, Hollis JM, Hollis GF and Friedman PA: Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 275: 39543-39554, 2000.
7. Gronke RS, Welsch DJ, Van Dusen WJ, Garsky VM, Sardana MK, Stern AM and Friedman PA: Partial purification and characterization of bovine liver aspartyl beta-hydroxylase. J Biol Chem 265: 8558-8565, 1990.
8. Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS and Friedman PA: Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo. J Pharmacol Exp Ther 302: 795-803, 2002.
9. Korioth F, Gieffers C and Frey J: Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase. Gene 150: 395-399, 1994.
10. 2+. Biochemistry 35: 3957-3962, 1996.
11. Ince N, de la Monte SM and Wands JR: Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 60: 1261-1266, 2000.
12. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR and Friedman PA: Overexpression of human aspartyl (asparaginyl) beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 98: 1313-1323, 1996.
13. de la Monte S, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, Lahousse SA, Califano S, Maeda T, Ueno T, D'Errico A, Trevisani F and Wands JR: Insulin receptor substrate-1 regulates aspartyl-asparaginyl-beta hydroxylase and hepatocellular carcinoma invasiveness. J Hepatol 44: 971-983, 2006.
14. Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR and de la Monte SM: Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 28: 313-318, 2004.
15. Palumbo KS, Wands JR, Safran H, King T, Carlson RI and de la Monte SM: Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 25: 39-44, 2002.
16. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR and de la Monte SM: Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 82: 881-891, 2002.
17. Xue T, Xue XP, Huang QS, Wei L, Sun K and Xue T: Monoclonal antibodies against human Aspartyl (Asparaginyl) beta-hydroxylase developed by DNA immunization. Hybridoma 28: 251-257, 2009.
18. Yang H, Chen JX, Yang GP, Zhang XH, Liu R and Xue XP: Protection of Japanese flounder (Paralichthys olivaceus) against Vibrio anguillarum with a DNA vaccine containing the mutated zinc-metalloprotease gene. Vaccine 27: 2150-2155, 2009.
19. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277: 680-685, 1970.
20. Treves S, Feriotto G, Moccagatta L, Gambari R and Zorzato F: Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane. J Biol Chem 275: 39555-39568, 2000.
21. Rockville, MD, PRNewswire/Panacea Pharmaceuticals, Inc. Oct. 23, 2002. (http://www.panaceapharma.com/press/10-23-2002.htm).
22. Rockville, MD, BW HealthWire/Panacea Pharmaceuticals, Inc. April 19, 2002. (http://www.panaceapharma.com/press/10-23-2002.htm).
23. Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K and Wu MC: Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. Modern Pathol 19: 280-286, 2006.
24. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR and de la Monte SM: Antisense oligodeoxy-nucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 38:615-622, 2003.
25. Hossein AG: Cancer diagnostics integrated with therapeutics: a comprehensive approach to managing the disease. J Biomed Biotechnol 4: 175-176, 2004.
26. Jia S, McGinnis K, Van Dusen WJ, Burke CJ, Kuo A, Griffin PR, Sardana MK, Elliston KO, Stern AM and Friedman PA: A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci USA 91: 7227-7231, 1994.
27. Jia S, Van Dusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, Stern AM and Friedman PA: cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem 267: 14322-14327, 1992.